Amedeo Smart

Free Medical Literature Service


 

Amedeo

Antiretroviral Therapy

  Free Subscription

Articles published in
Ann Intern Med
    February 2024

  1. Correction: SARS-CoV-2 Virologic Rebound With Nirmatrelvir-Ritonavir Therapy.
    Ann Intern Med. 2024 Feb 20. doi: 10.7326/L24-0045.
    >> Share

    January 2024
  2. CHAGLA Z
    In outpatients with COVID-19 during Omicron variant circulation, molnupiravir and nirmatrelvir-ritonavir improved outcomes.
    Ann Intern Med. 2024 Jan 2. doi: 10.7326/J23-0108.
    >> Share

  3. CENTOR RM, Cohen MS
    Annals On Call - COVID-19 Rebound After Nirmatrelvir-Ritonavir Treatment.
    Ann Intern Med. 2024;177:eA230002.
    >> Share

    November 2023
  4. COHEN MS, Brown ER
    Rebound of COVID-19 With Nirmatrelvir-Ritonavir Antiviral Therapy.
    Ann Intern Med. 2023 Nov 14. doi: 10.7326/M23-2887.
    >> Share

  5. EDELSTEIN GE, Boucau J, Uddin R, Marino C, et al
    SARS-CoV-2 Virologic Rebound With Nirmatrelvir-Ritonavir Therapy : An Observational Study.
    Ann Intern Med. 2023 Nov 14. doi: 10.7326/M23-1756.
    >> Share

    October 2023
  6. IOANNOU GN, Berry K, Rajeevan N, Li Y, et al
    Effectiveness of Nirmatrelvir-Ritonavir Against the Development of Post-COVID-19 Conditions Among U.S. Veterans : A Target Trial Emulation.
    Ann Intern Med. 2023 Oct 31. doi: 10.7326/M23-1394.
    >> Share

  7. FOCOSI D, Nicastri E
    Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Hospitalized Patients With COVID-19.
    Ann Intern Med. 2023;176:eL230264.
    >> Share

  8. WAN EYF, Yan VKC, Mok AHY, Wong ICK, et al
    Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Hospitalized Patients With COVID-19.
    Ann Intern Med. 2023;176:eL230265.
    >> Share

    September 2023
  9. SOMMER I, Ledinger D, Thaler K, Dobrescu A, et al
    Outpatient Treatment of Confirmed COVID-19: A Living, Rapid Evidence Review for the American College of Physicians (Version 2).
    Ann Intern Med. 2023 Sep 19. doi: 10.7326/M23-1626.
    >> Share

  10. QASEEM A, Yost J, Abraham GM, Andrews R, et al
    Outpatient Treatment of Confirmed COVID-19: Living, Rapid Practice Points From the American College of Physicians (Version 2).
    Ann Intern Med. 2023 Sep 19. doi: 10.7326/M23-1636.
    >> Share

    June 2023
  11. BAJEMA KL, Berry K, Streja E, Rajeevan N, et al
    Effectiveness of COVID-19 Treatment With Nirmatrelvir-Ritonavir or Molnupiravir Among U.S. Veterans: Target Trial Emulation Studies With One-Month and Six-Month Outcomes.
    Ann Intern Med. 2023 Jun 6:M22-3565. doi: 10.7326/M22-3565.
    >> Share

    March 2023
  12. HERNAN MA, Del Amo J
    Drug Repurposing and Observational Studies: The Case of Antivirals for the Treatment of COVID-19.
    Ann Intern Med. 2023 Mar 28. doi: 10.7326/M22-3582.
    >> Share

  13. WAN EYF, Yan VKC, Mok AHY, Wang B, et al
    Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Hospitalized Patients With COVID-19 : A Target Trial Emulation Study.
    Ann Intern Med. 2023 Mar 14. doi: 10.7326/M22-3057.
    >> Share

    February 2023
  14. DEO R, Choudhary MC, Moser C, Ritz J, et al
    Symptom and Viral Rebound in Untreated SARS-CoV-2 Infection.
    Ann Intern Med. 2023 Feb 21. doi: 10.7326/M22-2381.
    >> Share

    December 2022
  15. DRYDEN-PETERSON S, Kim A, Kim AY, Caniglia EC, et al
    Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large U.S. Health System : A Population-Based Cohort Study.
    Ann Intern Med. 2022 Dec 13. doi: 10.7326/M22-2141.
    >> Share

  16. ANESI GL, Maguire C
    Nirmatrelvir Plus Ritonavir for Ambulatory COVID-19: Expanding Evidence, Expanding Role.
    Ann Intern Med. 2022 Dec 13. doi: 10.7326/M22-3427.
    >> Share

    November 2022
  17. QASEEM A, Yost J, Miller MC, Andrews R, et al
    Outpatient Treatment of Confirmed COVID-19: Living, Rapid Practice Points From the American College of Physicians (Version 1).
    Ann Intern Med. 2022 Nov 29. doi: 10.7326/M22-2249.
    >> Share

  18. SOMMER I, Dobrescu A, Ledinger D, Moser I, et al
    Outpatient Treatment of Confirmed COVID-19 : A Living, Rapid Review for the American College of Physicians.
    Ann Intern Med. 2022 Nov 29. doi: 10.7326/M22-2202.
    >> Share

    June 2022
  19. VASSILOPOULOS A, Mylonakis E
    In patients with COVID-19 at risk for severe disease, nirmatrelvir + ritonavir reduced hospitalization or death.
    Ann Intern Med. 2022 Jun 7. doi: 10.7326/J22-0038.
    >> Share

    March 2022
  20. MARZOLINI C, Kuritzkes DR, Marra F, Boyle A, et al
    Prescribing Nirmatrelvir-Ritonavir: How to Recognize and Manage Drug-Drug Interactions.
    Ann Intern Med. 2022 Mar 1. doi: 10.7326/M22-0281.
    >> Share

    February 2022
  21. NEILAN AM, Landovitz RJ, Le MH, Grinsztejn B, et al
    Cost-Effectiveness of Long-Acting Injectable HIV Preexposure Prophylaxis in the United States : A Cost-Effectiveness Analysis.
    Ann Intern Med. 2022 Feb 1. doi: 10.7326/M21-1548.
    >> Share

    October 2021
  22. SIEDNER MJ, Moosa MS, McCluskey S, Gilbert RF, et al
    Resistance Testing for Management of HIV Virologic Failure in Sub-Saharan Africa : An Unblinded Randomized Controlled Trial.
    Ann Intern Med. 2021 Oct 26. doi: 10.7326/M21-2229.
    >> Share

    April 2021
  23. TITANJI B, Hernandez-Romieu AC, Adelman MW
    Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy.
    Ann Intern Med. 2021;174:580-581.
    >> Share

  24. DEL AMO J, Polo R, Moreno S, Diaz A, et al
    Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy.
    Ann Intern Med. 2021;174:581-582.
    >> Share

    March 2021
  25. SURIAL B, Mugglin C, Calmy A, Cavassini M, et al
    Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV : A Cohort Study.
    Ann Intern Med. 2021 Mar 16. doi: 10.7326/M20-4853.
    >> Share


  26. Summary for Patients: Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV.
    Ann Intern Med. 2021 Mar 16. doi: 10.7326/P21-0002.
    >> Share

    February 2021
  27. ZHANG R, Mylonakis E
    In inpatients with COVID-19, none of remdesivir, hydroxychloroquine, lopinavir, or interferon beta-1a differed from standard care for in-hospital mortality.
    Ann Intern Med. 2021 Feb 2. doi: 10.7326/ACPJ202102160.
    >> Share

    January 2021
  28. SINGH A
    In severe COVID-19, adding lopinavir-ritonavir to usual care did not improve mortality at 28 days.
    Ann Intern Med. 2021 Jan 5. doi: 10.7326/ACPJ202101190.
    >> Share

    September 2020
  29. DAS M, Ting J, Shreay S, Bush S, et al
    Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis.
    Ann Intern Med. 2020;173:506-507.
    >> Share

  30. WALENSKY RP, Horn T, McCann NC, Freedberg KA, et al
    Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis.
    Ann Intern Med. 2020;173:507-508.
    >> Share

  31. FURUKAWA NW, Zhu W, Huang YA, Shrestha RK, et al
    National Trends in Drug Payments for HIV Preexposure Prophylaxis in the United States, 2014 to 2018 : A Retrospective Cohort Study.
    Ann Intern Med. 2020 Sep 8. doi: 10.7326/M20-0786.
    >> Share

    July 2020
  32. BRAINARD D, McCallister S
    Tenofovir Alafenamide for HIV Preexposure Prophylaxis.
    Ann Intern Med. 2020;173:77-78.
    >> Share

  33. KRAKOWER DS, Daskalakis DC, Feinberg J, Marcus JL, et al
    Tenofovir Alafenamide for HIV Preexposure Prophylaxis.
    Ann Intern Med. 2020;173:78.
    >> Share

    June 2020
  34. DEL AMO J, Polo R, Moreno S, Diaz A, et al
    Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy: A Cohort Study.
    Ann Intern Med. 2020 Jun 26. doi: 10.7326/M20-3689.
    >> Share

  35. YANG P, Tekwani S, Martin GS
    In COVID-19, adding lopinavir-ritonavir to usual care did not shorten time to clinical improvement.
    Ann Intern Med. 2020;172:JC63.
    >> Share

    May 2020
  36. SCHOERGENHOFER C, Jilma B, Stimpfl T, Karolyi M, et al
    Pharmacokinetics of Lopinavir and Ritonavir in Patients Hospitalized With Coronavirus Disease 2019 (COVID-19).
    Ann Intern Med. 2020 May 12. doi: 10.7326/M20-1550.
    >> Share

  37. DEL RIO C, Armstrong WS
    How Much Are We Willing to Pay for Preexposure Prophylaxis in the United States?
    Ann Intern Med. 2020;172:623-624.
    >> Share

    March 2020
  38. WALENSKY RP, Horn T, McCann NC, Freedberg KA, et al
    Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis: A Cost-Effectiveness Analysis.
    Ann Intern Med. 2020 Mar 10. pii: 2762726. doi: 10.7326/M19-3478.
    >> Share

    February 2020
  39. LEVY Y, Lelievre JD, Assoumou L, Aznar E, et al
    Addition of Maraviroc Versus Placebo to Standard Antiretroviral Therapy for Initial Treatment of Advanced HIV Infection: A Randomized Trial.
    Ann Intern Med. 2020 Feb 11. pii: 2760879. doi: 10.7326/M19-2133.
    >> Share

    January 2020
  40. KRAKOWER DS, Daskalakis DC, Feinberg J, Marcus JL, et al
    Tenofovir Alafenamide for HIV Preexposure Prophylaxis: What Can We DISCOVER About Its True Value?
    Ann Intern Med. 2020 Jan 14. pii: 2758848. doi: 10.7326/M19-3337.
    >> Share

    October 2019
  41. BAHR NC, Yarlagadda SG
    Fanconi Syndrome and Tenofovir Alafenamide.
    Ann Intern Med. 2019;171:599-600.
    >> Share

  42. ALVAREZ H, Llibre JM
    Fanconi Syndrome and Tenofovir Alafenamide.
    Ann Intern Med. 2019;171:598-599.
    >> Share

    May 2019
  43. HOFFMAN RM, Mofenson LM
    Decision Making in a Time of Uncertainty: Dolutegravir for Reproductive-Age Women.
    Ann Intern Med. 2019;170:658-659.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016